Related Experiment Video
Updated: Jun 4, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Non interventional drug studies in oncology: Why we need them?
1Division of Medical and Research, Pfizer Limited Patel Estate, Off S.V. Road, Jogeshwari (West), Mumbai - 400 102, Maharashtra, India.
Abstract:
Oncology is a highly researched therapeutic area with an ever expanding armamentarium of drugs entering the market. It is unique in how the heterogeneity of tumor, patient and treatment factors is critical in determining outcomes of interventions. When it comes to decision making in the clinic, the practicing physician often seeks answers in populations with obvious deviations from the ideal selected populations included in the pivotal phase III randomized controlled trials (RCTs). While the randomized nature of the RCT ensures its high internal validity by removing bias, their 'controlled' nature casts a doubt on their generalizability to the real world population. It is for this reason that trials done in a naturalistic setting post the marketing authorization of a drug are increasingly required. This article discusses the importance of non interventional drug studies in oncology as an important tool in testing the external validity of controlled trial results and its value in generation of new hypothesis. It also discusses the limitations of such studies while outlining the steps in their effective conduct.
Insights
Non-interventional drug studies in oncology are crucial for validating real-world treatment effectiveness. These studies bridge the gap between controlled trials and clinical practice, enhancing drug safety and efficacy insights.
Area of Science:
- Oncology
- Clinical Pharmacology
- Real-world Evidence
Background:
- Oncology drug development faces challenges due to patient heterogeneity.
- Pivotal Phase III Randomized Controlled Trials (RCTs) often use highly selected populations, limiting generalizability.
- Physicians require real-world data to inform treatment decisions for diverse patient groups.
Purpose of the Study:
- To highlight the importance of non-interventional drug studies in oncology.
- To assess the external validity of controlled trial findings in real-world settings.
- To explore the value of these studies in hypothesis generation and effective conduct.
Main Methods:
- Discussion of the role of non-interventional studies post-marketing authorization.
- Analysis of how these studies test the external validity of RCTs.
- Outline of practical steps for conducting effective non-interventional drug studies.
Main Results:
- Non-interventional studies are vital for assessing real-world drug performance.
- These studies complement RCTs by evaluating outcomes in broader patient populations.
- They provide valuable data for hypothesis generation and refining clinical practice.
Conclusions:
- Non-interventional studies are essential for understanding drug effectiveness in routine oncology care.
- They bridge the gap between internal validity from RCTs and external validity in clinical practice.
- Effective conduct of these studies is key to maximizing their value in oncology research.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioavailability Study Design: Healthy Subjects Versus Patients
Preclinical Development: Overview
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

